NewsStackNewsStack
Daily Brief: Which companies are hyping vs delivering: red flags, real signals and repeat offenders, free daily.

Surgery Partners, Inc. Announces Increased Consent Fee in Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032

18 Nov 2026🟡 Routine Noise
Share𝕏inf

Surgery Partners doubles consent fee to $5 for $1.225B notes ahead of acquisition vote.

What the company is saying

Surgery Partners, Inc., through its subsidiary Surgery Center Holdings, Inc., is amending its consent solicitation for $1,225,000,000 of 7.250% Senior Notes due 2032. The company is increasing the consent fee from $2.50 to $5.00 per $1,000 in principal for holders who deliver valid consents before the November 20, 2026 deadline. The announcement emphasizes that payment of the increased fee is contingent on receiving consents from holders of a majority of the notes, as defined in the indenture, and on satisfaction or waiver of other conditions in the Consent Solicitation Statement. The company clarifies that holders who already consented do not need to take further action and that those who do not consent or revoke will not receive the fee. The process is framed as procedural, with Jefferies LLC as solicitation agent and S&P Global Inc. as information and tabulation agent. The company also references the ongoing proposed acquisition by an affiliate of Bon Secours Mercy Health, Inc., and the upcoming SEC filings, but does not provide operational or financial performance updates.

What the data suggests

The key disclosed figures are the $1,225,000,000 aggregate principal of the 7.250% Senior Notes due 2032 and the increase in the consent fee from $2.50 to $5.00 per $1,000 of principal. The consent solicitation expires at 5:00 p.m. New York City time on November 20, 2026, just two days after the announcement. Payment of the increased fee is conditional on majority holder consent and other terms in the Consent Solicitation Statement. No data is provided on current consent levels, operational results, or financial performance. The only financial direction implied is a willingness to pay a higher fee to secure noteholder support for amendments, likely related to the pending acquisition. The disclosure is complete for the consent process, but does not allow assessment of business trajectory or underlying financial health.

Analysis

The announcement is procedural, focused on amending the consent solicitation for outstanding senior notes by increasing the consent fee. All language is factual, with clear disclosure of the new fee, relevant dates, and process mechanics. While some statements are forward-looking (e.g., payment of the increased fee is conditional on certain events), these are standard for such processes and not promotional or exaggerated. There are no claims of operational, financial, or strategic improvement, nor any attempt to frame the amendment as a value-creating event. No large capital outlay is being newly committed; the $1.225 billion principal is pre-existing, and the incremental consent fee is modest. The tone is neutral, and there is no narrative inflation or overstatement relative to the evidence provided.

Risk flags

  • ●There is execution risk if holders of a majority of the $1,225,000,000 notes do not deliver consents, which would prevent the proposed amendments and payment of the increased fee.
  • ●The increased consent fee raises the cost of securing noteholder support, which could marginally impact transaction economics, especially if the acquisition does not close.
  • ●The proposed acquisition by an affiliate of Bon Secours Mercy Health, Inc. is still subject to regulatory approvals, stockholder votes, and other closing conditions, any of which could delay or derail the transaction and affect the rationale for the consent solicitation.

Bottom line

Surgery Partners is offering a higher $5.00 per $1,000 consent fee to holders of $1.225 billion in senior notes to secure approval for amendments likely tied to its pending acquisition. The process is tightly defined, with a near-term deadline and payment contingent on majority consent and other procedural conditions. No operational or financial performance data is disclosed, so investors cannot assess business momentum or acquisition impact from this release. The main takeaway is that management is willing to pay more to ensure noteholder alignment ahead of a transformative transaction. Investors should watch for the outcome of the consent process and subsequent SEC filings related to the acquisition, as these will determine the next phase of the company's capital structure and ownership.

Announcement summary

(NASDAQ:SGRY) Surgery Partners, Inc. announced that its indirect wholly owned subsidiary, Surgery Center Holdings, Inc., has amended its previously announced consent solicitation from holders of its outstanding $1,225,000,000 aggregate principal amount of 7.250% Senior Notes due 2032. The amendment increases the consent fee payable to holders who validly deliver (and do not validly revoke) consents prior to the expiration time from $2.50 to $5.00 per $1,000 in principal amount of Notes. The Consent Solicitation is being conducted in accordance with the terms and subject to the conditions set forth in the Consent Solicitation Statement dated November 16, 2026, as amended by Amendment No. 1 dated November 16, 2026, and Amendment No. 2 dated November 18, 2026. The Consent Solicitation is scheduled to expire at 5:00 p.m., New York City time, on November 20, 2026, unless extended or earlier terminated. Holders who have already delivered (and not validly revoked) consents do not need to take further action to be eligible for the increased consent fee. Payment of the increased consent fee is conditioned upon satisfaction or waiver of the conditions set forth in the Consent Solicitation Statement, including receipt of consents from holders of a majority of the aggregate principal amount of the Notes outstanding, calculated in accordance with the indenture. If these conditions are satisfied or waived, the increased consent fee will be paid promptly following the later of the expiration time and the effective time, whether or not the merger referenced in the Consent Solicitation Statement is consummated. Holders who do not deliver consents, or who validly revoke their consents, will not receive the increased consent fee. Except as described, the terms of the Consent Solicitation remain unchanged. Jefferies LLC is serving as solicitation agent, and S&P Global Inc. is serving as information and tabulation agent for the Consent Solicitation. The Consent Solicitation is not an offer to purchase or sell the Notes or any other securities. In connection with the proposed acquisition by an affiliate of Bon Secours Mercy Health, Inc. of the company, Surgery Partners will file a proxy statement and a Schedule 13E-3 with the SEC. The company and certain directors, executive officers, and employees may be deemed participants in the solicitation of proxies in connection with the proposed transactions. Additional information regarding the participants and their interests will be set forth in the proxy statement and Schedule 13E-3 and other materials to be filed with the SEC. No person has commenced soliciting proxies in connection with the proposed transactions referenced in this communication.

Disagree with this article?

Ctrl + Enter to submit